• Publications
  • Influence
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.
Apoptosis is a highly regulated form of cell death that controls normal homeostasis as well as the antitumor activity of many chemotherapeutic agents. Commitment to death via the mitochondrialExpand
  • 163
  • 15
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.
miRNAs are small RNA molecules binding to partially complementary sites in the 3'-UTR of target transcripts and repressing their expression. miRNAs orchestrate multiple cellular functions and playExpand
  • 247
  • 12
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, weExpand
  • 160
  • 9
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
The mitochondrial state of a tumor cell prior to chemotherapy may help determine how well it responds to drug treatment. Cytotoxic chemotherapy targets elements common to all nucleated human cells,Expand
  • 409
  • 8
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Significance Poly(ADP-ribose) polymerase (PARP) inhibitors have produced responses in homologous recombination (HR) repair-deficient cancers, such as those with a mutated breast cancer 1, early onsetExpand
  • 138
  • 7
Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.
It is not understood why healthy tissues can exhibit varying levels of sensitivity to the same toxic stimuli. Using BH3 profiling, we find that mitochondria of many adult somatic tissues, includingExpand
  • 96
  • 6
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer patients. While most efforts are directed at inferring drug response phenotype based on genotype,Expand
  • 201
  • 4
PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.
Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed enzyme shown to negatively regulate multiple tyrosine phosphorylation-dependent signaling pathways. PTP1B can modulate cytokineExpand
  • 104
  • 4
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
The loss of vital cells within healthy tissues contributes to the development, progression and treatment outcomes of many human disorders, including neurological and infectious diseases as well asExpand
  • 133
  • 3
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR. Here, weExpand
  • 89
  • 3